Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, non prostate

1957 - Tumor molecular characteristics in patients (pts) with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) good (G) and intermediate/poor (I/P) risk


20 Oct 2018


Poster Discussion session - Genitourinary tumours, non prostate


Pathology/Molecular Biology

Tumour Site

Renal Cell Cancer


Benoit Beuselinck


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


B. Beuselinck1, A.T.L. Verbiest2, G. Couchy3, S. Job4, A. de Reyniès4, S. Caruso3, V. Verkarre5, N. Rioux-Leclercq6, P. Schöffski1, Y. Vano7, R. Elaidi8, E. Lerut9, M. Albersen10, S. Oudard11, J. Zucman-Rossi12

Author affiliations

  • 1 General Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 2 Laboratory Of Medical Oncology, KU Leuven, 3000 - Leuven/BE
  • 3 U1162, INSERM, 75010 - Paris/FR
  • 4 Biostatistique, La Ligue Contre Le Cancer, 75014 - Paris/FR
  • 5 Pathologie, Hôpital Necker Enfants malades, 75015 - Paris/FR
  • 7 Oncologie Médicale, HEGP, 75015 - Paris/FR
  • 8 Oncologie Médicale, ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, 75015 - Paris/FR
  • 9 Pathology, University Hospitals Leuven, 3000 - Leuven/BE
  • 10 Urology, University Hospitals Leuven, 3000 - Leuven/BE
  • 11 Immunothérapie Et Traitement Antiangiogénique En Pathologie cancérologique, Hopital European George Pompidou, 75015 - Paris/FR
  • 12 Oncologie Médicale, Université Paris Descartes, 75006 - Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1957


In advanced clear cell renal cell carcinoma (ccRCC), Checkmate214 demonstrated superior response rates (RR) and progression-free survival (PFS) with ipilimumab/nivolumab (IPI/NIVO) in IMDC I/P-risk pts and with sunitinib (SUN) in G-risk pts. We aimed to study the underlying biologic mechanisms.


We have recently proposed four molecular ccRCC subtypes: ccrcc2-tumors, characterized by a pro-angiogenic gene signature, respond well to SUN, while ccrcc1- and 4-tumors are intermediate and poor responders to SUN. We analyzed our ccRCC databank and correlated the IMDC prognostic score at start of systemic therapy with mRNA-expression of genes involved in angiogenesis (HIF1A/2A, VEGFA, VEGFR1/2/3) and in the immunosuppressive microenvironment (PD1, PDL1/2, LAG3, CD8A, CD3G, IFNG, CXCL13) and with the molecular ccrcc1-4 classification of the primary tumor.Table: 869PD

IMDC G-riskIMDC I/P-riskp (+difference in %)Test
MOLECULAR SUBTYPESccrcc114% (3/22)34% (47/140)0.08Fisher exact
ccrcc277% (17/22)41% (59/140)0.002
ccrcc39% (2/22)5% (7/140)0.35
ccrcc40% (0/22)20% (28/140)0.02
PRO-ANGIOGENIC GENE EXPRESSION (deltadeltaCT)HIF1A0.820.630.21 (+29%)Student’s test
HIF2A1.220.780.03 (+57%)
VEGFA7.104.260.07 (+67%)
VEGFR13.061.530.02 (+100%)
VEGFR21.370.600.009 (+128%)
VEGFR31.070.710.03 (+52%)
OUTCOME ON FIRST-LINE VEGFR-TKI (n = 151)RR63%40%0.08Fisher exact
PFS (months)25100.03


162 pts were included (14% IMDC G-, 65% I- and 21% P-risk). The majority of G-risk pts (77%) had ccrcc2-tumors. ccrcc1- (14%) and ccrcc4-tumors (0%) were less frequent. In I/P-risk pts, ccrcc2-tumors were less frequent (41%), and ccrcc1- (34%) and ccrcc4-tumors (20%) more frequent. mRNA expression of HIF2A, VEGFR1, -2 and -3 was higher in G-risk pts compared to I/P-risk pts. Identical expression of immune related genes was found across all IMDC subgroups.


The majority of IMDC G-risk ccRCCs pts have ccrcc2-tumors. G-risk pts display a higher expression of the VEGF-dependent pro-angiogenic pathway, compared to I/P-risk pts. This may explain the increased benefit of SUN over IPI/NIVO in G-risk pts in Checkmate214.

Clinical trial identification

Legal entity responsible for the study

University Hospitals Leuven.


La Ligue Contre le Cancer France.

Editorial Acknowledgement


B. Beuselinck: Speeker's fee, Research grant: Pfizer P. Schöffski: Institutional travel grant: Pfizer. S. Oudard: Speeker's fee: Pfizer All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.